PriceTargets.com logo

Cerecor - CERC Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$15.94 As of 04/26/2024 01:00 AM ET
▲ +0.96 (6.41%)
Get New Cerecor Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CERC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CERC

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Cerecor in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $15.94.

This chart shows the closing price for CERC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Cerecor. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021Cantor FitzgeraldInitiated CoverageOverweight$7.00High
4/21/2021Maxim GroupUpgradeHold ➝ Buy$7.00High
4/20/2021Jefferies Financial GroupInitiated CoverageBuy$4.00High
3/21/2021OppenheimerReiterated RatingBuy$9.00Medium
6/7/2020LADENBURG THALM/SH SHReiterated RatingBuy$10.00High
5/13/2020OppenheimerLower TargetOutperform$11.00 ➝ $10.00High
4/15/2020HC WainwrightReiterated RatingBuyMedium
3/13/2020Maxim GroupDowngradeBuy ➝ HoldHigh
1/10/2020OppenheimerInitiated CoverageOutperform$11.00High
12/6/2019LADENBURG THALM/SH SHReiterated RatingBuy$10.00High
12/2/2019HC WainwrightReiterated RatingBuy$11.00 ➝ $12.00Medium
11/15/2019Maxim GroupReiterated RatingBuy$10.00High
10/15/2019Maxim GroupReiterated RatingBuy$10.00Low
8/21/2019HC WainwrightSet TargetBuy$11.00High
8/9/2019Maxim GroupSet TargetBuy$10.00Medium
7/15/2019HC WainwrightSet TargetBuy$11.00Low
7/2/2019Maxim GroupReiterated RatingBuy$10.00Medium
7/2/2019LADENBURG THALM/SH SHReiterated RatingBuy$8.00High
5/28/2019HC WainwrightReiterated RatingBuy$11.00Low
5/13/2019LADENBURG THALM/SH SHReiterated RatingBuy$8.00High
5/10/2019Maxim GroupReiterated RatingBuy$10.00High
4/29/2019HC WainwrightReiterated RatingBuy$11.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Cerecor logo
Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.
Read More

Today's Range

Now: $15.94
Low: $14.69
High: $16.23

50 Day Range

MA: $2.60
Low: $2.06
High: $3.24

52 Week Range

Now: $15.94
Low: $1.98
High: $4.50

Volume

78,100 shs

Average Volume

1,265,434 shs

Market Capitalization

$1.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Cerecor?

The following Wall Street analysts have issued research reports on Cerecor in the last year:
View the latest analyst ratings for CERC.

What is the current price target for Cerecor?

0 Wall Street analysts have set twelve-month price targets for Cerecor in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Cerecor in the next year.
View the latest price targets for CERC.

What is the current consensus analyst rating for Cerecor?

Cerecor currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CERC.

What other companies compete with Cerecor?

Other companies that are similar to Cerecor include Kiniksa Pharmaceuticals, Pacira BioSciences, Spyre Therapeutics, Ligand Pharmaceuticals and Verona Pharma. Learn More about companies similar to Cerecor.

How do I contact Cerecor's investor relations team?

Cerecor's physical mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company's listed phone number is (410) 522-8707 and its investor relations email address is [email protected]. The official website for Cerecor is www.cerecor.com. Learn More about contacing Cerecor investor relations.